Psychedelics Company Atai Life Sciences Files For Nasdaq Listing
NEW YORK– Atai Life Sciences are priming to become the second psychedelics company to list on a major U.S. exchange, following COMPASS Pathways (to which Atai is connected). The German headquartered biotech firm filed Tuesday with the SEC to raise $100 million in an IPO using the ticker symbol “ATAI.”
With a portfolio of about 12 companies, Atai is an aggretator of mental health startups providing alternative solutions to mental health treatment. It also provides support to other ventures in the same arena. Its portfolio includes companies develpoing therapies involving Ketaime, MDMA, ibogaine and DMT. Atai’s revenue stream is still dependent on the regulatory approval of the compounds and treatments in its pipeline.
Its portfolio includes companies develpoing therapies involving Ketaime, MDMA, ibogaine and DMT.
Atai’s revenue stream is still dependent on the regulatory approval of the compounds and treatments in its pipeline.
Backed by investor Peter Thiel, (pictured), Atai owns a 25% stake in Compass Pathways (NASDAQ: CMPS), a company developing psilocybin products for psychedelics-assisted psychotherapy, which debuted on Wall Street in September of last year.
Atai also provides companies in its portfolio with R&D infrastructure, legal, financial and accounting operations.
“The common thread, the bridge across all of these companies is the Atai personnel. We are heavily, heavily operationally involved, certainly on the development side, but beyond in all of these companies,” Srinivas Rao, chief scientific officer at Atai, said in a recent interview reported by Yahoo Finance.
(This information is primarily sourced from Atai and other sources. Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here).Credit: Getty Images/John Lamparski
Latest News
3,000 Cannabis Leaders And Investors To Convene At World’s Largest Cannabis Business And Investment Conference, April 11-12 In Miami Beach
The 16th edition of the Benzinga Cannabis Capital Conference, the world's largest gathering of high-impact decision-makers, founders, and investors in the cannabis industry, is set to take place at the Fontainebleau Miami Beach Hotel on ...
A Mother’s Journey to Save Her Son Through Cannabidiol Therapy
"Mighty Flower: How Cannabis Saved My Son," written by Dr. Annabelle Manalo-Morgan, Ph.D., is now available. Published by Forbes Books, the book is a mix of personal memoir and examination of the growth of medicinal ...
Survey Reveals Majority of American Adults Plan to Use or Gift Cannabis This Valentine’s Day
NEW YORK - Move over roses! A different type of “flower” may be taking over Valentine’s Day. Data from a recent online survey conducted by Wired Research found that 3 in 5 (61%) American adults ...